Polycystic kidney disease, PLD polycystic liver disease, and certain rare diseases are among those that have used long acting injectable once a month analog of somatostatin.
ACROMEGALY J Formos Med Assoc. 2006 Aug;105(8):664-9. Su DH, Liao KM, Chen HW, Chang TC.
Far Eastern Polyclinic, Taipei, Taiwan.
Long-term treatment with somatostatin analogs offers an alternative choice in selected acromegalic patients.
ACROMEGALY Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):424-5. Hoffman AR.
Endocrine Section, Veterans Affairs Palo Alto Health Care System, CA 94304, USA. email@example.com
Partial tumor debulking enhances the response to somatostatin in acromegaly.
ACROMEGALY University of Naples, 80131 Naples, Italy
Cardiovascular Effects of Depot Long Acting Somatostatin Analog Sandostatin LAR in Acromegaly
LIVER CIRRHOSIS Medizinische Klinik und Poliklinik I, Allgemeine Innere Medizin, University of Bonn, Germany. firstname.lastname@example.org
Effect of somatostatin on meal stimulated portal blood flow with liver cirrhosis
LUPUS 2006;15(8):526-31. Paran D, Bernheim J, Golan I, Caspi D, Bernheim J, Benchetrit S. Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Israel. Parand@netvision.net.il
Somatostatin treatment attenuates proteinuria and prevents weight loss in Lupus mice. Further studies will be needed to assess the value of Somatostatin, a naturally occurring neuropeptide in the treatment in lupus nephritis, suggesting beneficial effect on renal parameters.
ADPKD Italian Study on Somatostatin
ADPKD Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. CONCLUSION: In ADPKD patients, 6-month somatostatin therapy is safe and may slow renal volume expansion. This may reflect an inhibited growth in particular of the smallest cysts beyond the detection threshold of CT scan evaluation.
ADPKD Does extended-release somatostatin slow the growth of renal cysts in autosomal-dominant polycystic kidney disease? Technological advances now allow cyst and kidney volumes to be accurately measured in individual patients using MRI. The course of PKD can be determined within a short period of time. Ruggenenti et al have certainly made a large crack in the wall that has hitherto prevented effective therapy for ADPKD.